|
Abstract To investigate the value of magnetic resonance imaging (MRI) combined with the levels of serum Nectin-2 and Nidogen-2 for differential diagnosing ovarian tumors. Methods: From June 2018 to June 2020, 100 patients with ovarian tumor were selected in this study, which included 68 patients with benign ovarian tumor in group A and 32 patients with malignant ovarian tumor in group B. The MRI features of the patients in the two groups were analyzed, and the expression levels of serum Nectin-2 and Nidogen-2 of the patients in the two groups were detected. The diagnostic value of MRI combined with serum Nectin-2 and Nidogen-2 levels for malignant ovarian tumor was evaluated by receiver operator characteristic curve. Results: The MRI features of malignant ovarian tumors were irregular edges, unclear boundaries, cystic solid mass, obvious enhancement of enhanced scan, and uneven signal, while the MRI features of benign ovarian tumors were regular edges, clear boundary, cystic mass, no enhancement or mild enhancement of enhanced scan, and uniform signal. There were significant differences in the distribution, morphology, boundary, tumor composition, and enhancement degree of the patients between group A and group B. The serum levels of Nectin-2 (5.36±1.64 ng/ml) and Nidogen-2 (30.23±9.35 ng/ml) of the patients in group B were significantly higher than those (2.87±0.95 ng/ml and 16.42±4.78 ng/ml) of the patients in group A (P＜0.05). The sensitivity of MRI combined with serum nectin-2 and Nidogen-2 levels for diagnosing benign or malignant ovarian tumors (93.8%) was significantly higher than that of MRI, serum nectin-2 level, or Nidogen-2 level alone (P＜0.05). The cut-off values of Nectin-2 and Nidogen-2 levels for diagnosing malignant ovarian tumor were 3.57 ng/ml and 25.62 ng/ml, respectively. Conclusion: MRI combined with the serum Nectin-2 and Nidogen-2 levels of the patients for diagnosing their benign or malignant ovarian tumors has high sensitivity.
|
|
|
|
|
|
